Greetings and welcome to the Genfit Half-year 2020 financial report and new Corporate Strategy Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]
I will now turn the conference over to our host Stephanie Magner. Please go ahead.
Thank you and good afternoon everyone. Thanks for joining us for this first half 2020 financial report and corporate update. We just issued a press release providing our first half financial update, which also included details about our new corporate and strategic roadmap this press release can be accessed on our website at ir.Genfit.com.
During our call, we'll be making forward-looking statements as defined under the US Private Securities Litigation Reform Act of 1995 with respect to Genfit our expected future performance, business prospects events and plans, including our new corporate strategy and objectives potential size of the market for PBC commercial certainty within this market an outcome of our latest Phase III study of elafibranor in PBC timelines for completion of the latest trial timelines for the success of the commercial launch of a diagnostic test powered by NIS 4 by our partner LabCorp test and benefits of corporate restructuring projects putting a workforce reduction program our ability to significantly reduce operating expenses, our projected cash flows over the next several years and our ability to adjust the terms of our convertible bond. These forward-looking statements are based on assumptions and estimates by our management, which although believe to be reasonable, are subject to numerous known and unknown risks and uncertainties which could cause actual results to differ materially from those expressed in or implied or projected by the forward-looking statements.
For further discussion of the material risks and other important factors that could affect our business operations and financial results, please refer to those contained in our most recent filings with the SEC and AMF including our half-year report available on our website. These forward-looking statements speak only as of the date of this webcast, other than as required by applicable law, the company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. Joining me on this call is Pascal Zhang, our CEO. Following the prepared remarks, we'll open up the call for questions. That will be addressed by Genfit management please limit yourself to one initial question to allow time for others.
I'll now turn the call over to our CEO Pascal Prigent.
Thank you, Stephanie, and good afternoon everyone. Thanks for joining this discussion for purpose of our webcast today is twofold. First presents the conclusions of the work we did following the announcement of the resolve it Phase 3 results in NASH and secondly discuss how the results redefine our corporate strategy and how we see its implementation moving forward. I'll start with key findings from the in-depth analysis is carried out over the summer.
On the full results.
Chief Executive Officer
Chief Operating Officer
We are pleased that you like our content! Sign Up now to access premium content for free, a very limited time offer.
Welcome! Create your account
You are successfully registered!
An activation link has been sent to your mail. Please activate and login.